Leah Sherwood

Articles by Leah Sherwood

This issue includes a Get to Know with Catherine Coombs, MD; a debate on time-limited frontline therapy in CLL, and more.
Read More
Leah SherwoodMyelofibrosis | September 16, 2023
Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease.
Phillip Scheinberg, MDMyelodysplastic Syndromes | September 8, 2023
"There's been a lot of focus on classifications and mutations: they're coming with a lot of force," Dr. Scheinberg said.
Leah SherwoodAcute Myeloid Leukemia | September 8, 2023
Enrolled patients must be aged 75 years or older or aged 18-74 years with specific comorbidities.
Leah SherwoodMeeting News | September 8, 2023
The trial will enroll approximately 346 patients with treatment-naive TP53-mutated disease or biallelic 17p deletions.
Elias Jabbour, MDAcute Lymphoblastic Leukemia | September 7, 2023
Dr. Jabbour presented data from the study at the Eleventh Annual Meeting of SOHO.
Cecilia BrownMeeting News | September 6, 2023
The Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO) began on Wednesday.
This issue includes BCT Editorial Board highlights, a Get to Know with John DiPersio, MD, PhD; a feature on ctDNA; and more.
Leah SherwoodMyelofibrosis | August 9, 2023
In June 2023, the manufacturer of the drug initiated XPORT-MF-034, a pivotal phase III clinical trial.
Leah SherwoodMyeloma | August 2, 2023
The US FDA and NMPA have approved IND applications for LBL-034 for the treatment of relapsed or refractory multiple myeloma.
Leah SherwoodAcute Myeloid Leukemia | July 28, 2023
The difference in infection rates between the treatment and placebo groups was not statistically significant.
Leah SherwoodAcute Lymphoblastic Leukemia | July 26, 2023
EMA CHMP adopted a positive opinion recommending the marketing authorization of JZP458.
Leah SherwoodMantle Cell Lymphoma | July 24, 2023
With a median follow up of 41 months, the three-year PFS and OS rates were 85% and 86%, respectively.
Leah SherwoodMantle Cell Lymphoma | July 24, 2023
The single-arm, phase II clinical trial enrolled 50 previously untreated patients with a median age of 69 years.
Leah SherwoodMantle Cell Lymphoma | July 23, 2023
The trial assessed discontinuation of ibrutinib treatment in patients with indolent clinical forms of MCL.
Leah SherwoodAcute Myeloid Leukemia | July 17, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Shambavi Richard, MDMyeloma | July 17, 2023
In June 2023, a patient death led to the US Food and Drug Administration pausing the iMMagine-1 study.
Leah SherwoodAggressive B-Cell Lymphoma | July 12, 2023
The CAR-T targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies.
Leah SherwoodHodgkin Lymphoma | July 10, 2023
In this video interview, Dr. Mats Ehinger discusses the future of flow cytometry in lymphoma diagnostics.
Leah SherwoodMyelodysplastic Syndromes | July 7, 2023
The FDA has removed the partial clinical hold on the TakeAim Leukemia phase I/II study of emavusertib.